肿瘤科

订阅

MedSci主页 / 所有栏目 / 肿瘤科

贝伐珠单抗新适应证有望获EMA批准

2012-10-26 奎妮 中国医学论坛报

贝伐珠单抗靶向药物
关注

　　9月20日，欧洲药品管理局（EMA）人用药品委员会（CHMP）宣布对正在申请的贝伐珠单抗新适应证持积极肯定的意见，新适应证为，贝伐珠单抗与卡铂和吉西他滨联用适用于首次复发的铂敏感性上皮性卵巢癌、输卵管癌和原发性腹膜癌患者，这些患者既往未接受过贝伐珠单抗、其他血管内皮生长因子（VEGF）抑制剂或VEGF受体靶向药物治疗。更新产品特性概要（SmPC）将在修订版CHMP欧盟公共评估报告（EPAR）中

　　9月20日，欧洲药品管理局（EMA）人用药品委员会（CHMP）宣布对正在申请的贝伐珠单抗新适应证持积极肯定的意见，新适应证为，贝伐珠单抗与卡铂和吉西他滨联用适用于首次复发的铂敏感性上皮性卵巢癌、输卵管癌和原发性腹膜癌患者，这些患者既往未接受过贝伐珠单抗、其他血管内皮生长因子（VEGF）抑制剂或VEGF受体靶向药物治疗。更新产品特性概要（SmPC）将在修订版CHMP欧盟公共评估报告（EPAR）中发表，并可在欧委会批准上市销售许可变更后查询。

　　目前在欧盟批准的适应证中，贝伐珠单抗可应用于转移性结直肠癌、转移性乳腺癌、晚期非小细胞肺癌、肾细胞癌及卵巢癌的一线治疗。



版权声明：
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料，版权均属于梅斯医学所有。非经授权，任何媒体、网站或个人不得转载，授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章，或“梅斯号”自媒体发布的文章，仅系出于传递更多信息之目的，本站仅负责审核内容合规，其内容不代表本站立场，本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系，我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1954789, encodeId=1e201954e89d9, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Mar 09 16:19:00 CST 2013, time=2013-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893577, encodeId=302818935e788, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94717, encryptionId=cecf94e17f9, topicName=适应证)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Mar 04 06:19:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317191, encodeId=3ef1131e1914b, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Oct 28 04:19:00 CST 2012, time=2012-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476925, encodeId=077214e692581, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Oct 28 04:19:00 CST 2012, time=2012-10-28, status=1, ipAttribution=)]
    2013-03-09 仁医06

    #贝伐珠#

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1954789, encodeId=1e201954e89d9, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Mar 09 16:19:00 CST 2013, time=2013-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893577, encodeId=302818935e788, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94717, encryptionId=cecf94e17f9, topicName=适应证)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Mar 04 06:19:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317191, encodeId=3ef1131e1914b, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Oct 28 04:19:00 CST 2012, time=2012-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476925, encodeId=077214e692581, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Oct 28 04:19:00 CST 2012, time=2012-10-28, status=1, ipAttribution=)]
    2013-03-04 muzishouyi

    #适应证#

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1954789, encodeId=1e201954e89d9, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Mar 09 16:19:00 CST 2013, time=2013-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893577, encodeId=302818935e788, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94717, encryptionId=cecf94e17f9, topicName=适应证)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Mar 04 06:19:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317191, encodeId=3ef1131e1914b, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Oct 28 04:19:00 CST 2012, time=2012-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476925, encodeId=077214e692581, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Oct 28 04:19:00 CST 2012, time=2012-10-28, status=1, ipAttribution=)]
    2012-10-28 fengyi812

    #EMA#

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1954789, encodeId=1e201954e89d9, content=<a href='/topic/show?id=e4f39220658' target=_blank style='color:#2F92EE;'>#贝伐珠#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92206, encryptionId=e4f39220658, topicName=贝伐珠)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=55683, createdName=仁医06, createdTime=Sat Mar 09 16:19:00 CST 2013, time=2013-03-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1893577, encodeId=302818935e788, content=<a href='/topic/show?id=cecf94e17f9' target=_blank style='color:#2F92EE;'>#适应证#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94717, encryptionId=cecf94e17f9, topicName=适应证)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=685a124, createdName=muzishouyi, createdTime=Mon Mar 04 06:19:00 CST 2013, time=2013-03-04, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1317191, encodeId=3ef1131e1914b, content=<a href='/topic/show?id=74916e0414' target=_blank style='color:#2F92EE;'>#EMA#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=6704, encryptionId=74916e0414, topicName=EMA)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a35a460, createdName=fengyi812, createdTime=Sun Oct 28 04:19:00 CST 2012, time=2012-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1476925, encodeId=077214e692581, content=<a href='/topic/show?id=c32e9220221' target=_blank style='color:#2F92EE;'>#贝伐#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=37, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=92202, encryptionId=c32e9220221, topicName=贝伐)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=ef557344179, createdName=sunrural_42825359, createdTime=Sun Oct 28 04:19:00 CST 2012, time=2012-10-28, status=1, ipAttribution=)]
    2012-10-28 sunrural_42825359

    #贝伐#

    0

相关资讯

JCO:贝伐珠单抗+CP未改善黑色素瘤预后

　BEAM，一项随机Ⅱ期临床研究显示，联合贝伐珠单抗与单纯CP（卡铂加紫杉醇）方案化疗相比，未能显著改善转移性黑色素瘤患者预后。文章11月30日在线发表于《临床肿瘤学杂志》（J Clin Oncol）。 原始文献: Kim KB, Sosman JA, Fruehauf JP, Linette GP, Markovic SN, McDermott DF, Weber JS, Nguyen H,

Drug Saf：贝伐珠单抗不良事件报告分析

贝伐珠单抗最初于2004年由美国FDA批准用于治疗转移性结肠癌和其他实体瘤，是第一个血管内皮生长因子(VEGF)抑制剂。但上市前的临床试验检测某些不良事件的能力有限，因此FDA和生产商需要收集和监测上市后的不良事件报告。 研究者从美国FDA不良事件报告系统(AERS)数据库中检索了2004年2月~2009年9月报告的贝伐珠单抗的新不良事件，对贝伐珠单抗和其他所有药物进行失衡分析，通过设置比例报告

ASCO 2012：贝伐珠单抗治疗结直肠癌进展荟萃

       解放军307医院 徐建明        近年来，抗血管生成靶向药物贝伐珠单抗（安维汀）在转移性结直肠癌（mCRC）领域发表了较多的临床研究成果，2012年美国临床肿瘤学会（ASCO）年会上刚刚公布的TML（ML18147）和DREAM研究对贝伐珠单抗的应用模式产生了一定影响，而同期公布的汇总分析则反

EJC：贝伐珠单抗与胃肠穿孔相关但可控

　　一些随机对照研究（RCT）表明，对于接受氟尿嘧啶为基础化疗的转移性结直肠癌患者，加用贝伐珠单抗可延长其总生存期和无进展生存期；但1%～2%的患者会发生胃肠穿孔（GIP）。 　　美国学者近期在线发表于《欧洲癌症杂志》（European Journal of Cancer）的一项基于社区的大型观察性队列研究表明，GIP发生率与RCT结果一致，但大部分GIP通过手术干预可成功得到控制。 　　该研

NICE指南草案不推荐贝伐珠单抗/卡培他滨治疗乳腺癌

       英国临床优化研究所(NICE)日前表示，将不会建议贝伐珠单抗联合卡培他滨治疗进展性转移性乳腺癌。在4月18日发布的新指南草案中，NICE指出，支持这种联合治疗的证据不足。目前已有2种含贝伐珠单抗的方案被欧盟批准作为进展性转移性乳腺癌的一线治疗，本次被NICE否定的方案是其中之一。        

BMJ:贝伐珠单抗和雷珠单抗治疗糖尿病黄斑水肿无显著性差异

    8月13日《英国医学杂志》（BMJ）在线发表的一项系统回顾和间接比较研究结果发现，贝伐珠单抗和雷珠单抗治疗糖尿病黄斑水肿的作用并无显著性差异，但仍需要进一步头对头的研究来证实。 　　数据来源于Medline （1996–2011年9月），Embase （1996–2011年9月）及临床对照试验中心注册数据库（Issue